Actively Recruiting
Study of Neoadjuvant Radiotherapy, CAPOX Chemotherapy, and Iparomlimab with Tuvonralimab QL1706 for Locally Advanced Rectal Cancer
Led by Zhongnan Hospital · Updated on 2026-09-21
108
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the use of radiotherapy combined with CAPOX chemotherapy and two immunotherapy drugs, iparomlimab and tuvonralimab QL1706, as a pre-surgery treatment for patients with locally advanced rectal cancer. This phase II clinical trial aims to improve tumor response rates, including complete pathological response, and to explore how biomarkers in blood and tumor tissue relate to treatment effectiveness. The study focuses especially on patients with microsatellite stable disease, where immunotherapy benefits are less clear. Participants receive pelvic radiotherapy with a possible adaptive boost, along with one cycle of CAPOX chemotherapy during the first week. Two weeks after radiotherapy, they receive four cycles of combined immunotherapy and chemotherapy every three weeks. Surgery to remove the tumor is performed two to three weeks after completing immunochemotherapy, followed by additional CAPOX chemotherapy as adjuvant treatment. The trial will assess response rates and safety throughout these phases. During the study, participants undergo regular assessments including tumor response evaluations, pathological examinations after surgery, and monitoring of adverse events. Key outcomes include pathological and clinical complete response rates, tumor regression, sphincter preservation, and survival rates over three years. Safety and tolerability are evaluated based on established adverse event criteria. The total participation period extends until study completion in 2029, with primary outcomes assessed one year after treatment.
CONDITIONS
Brief Title
Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC
Research Team
Y
Yongchang Wei
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here